Davendra P S Sohal1, Erin B Kennedy2, Pelin Cinar3, Thierry Conroy4, Mehmet S Copur5, Christopher H Crane6, Ignacio Garrido-Laguna7, Michelle W Lau8, Tyler Johnson9, Smitha Krishnamurthi10, Cassadie Moravek11, Eileen M O'Reilly6, Philip A Philip12, Shubham Pant13, Manish A Shah14, Vaibhav Sahai15, Hope E Uronis16, Neeha Zaidi17, Daniel Laheru18. 1. University of Cincinnati, Cincinnati, OH. 2. American Society of Clinical Oncology, Alexandria, VA. 3. University of California, San Francisco, San Francisco, CA. 4. Université de Lorraine and Institut de Cancérologie de Lorraine, Lorraine, France. 5. Morrison Cancer Center, Hastings, NE. 6. Memorial Sloan Kettering Cancer Center, New York, NY. 7. Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT. 8. Phoenix VA Medical Center, Phoenix, AZ. 9. Stanford University, Palo Alto, CA. 10. Cleveland Clinic, Cleveland, OH. 11. Pancreatic Cancer Action Network, Manhattan Beach, CA. 12. Barbara Ann Karmanos Cancer Institute, Farmington Hills, MI. 13. MD Anderson Cancer Center, Houston, TX. 14. New York Presbyterian/Weill Cornell Medical Center, New York, NY. 15. University of Michigan, Ann Arbor, MI. 16. Duke University, Durham, NC. 17. Johns Hopkins Medicine, Baltimore, MD. 18. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Abstract
PURPOSE: The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS: ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS: One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS: New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
PURPOSE: The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS: ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS: One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS: New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
Authors: Patrick M McCarthy; Matthew J Rendo; Matthew D Uy; Alexandra M Adams; Anne E O'Shea; Daniel William Nelson; Joshua L Fenderson; Katherine M Cebe; Robert W Krell; Guy T Clifton; George E Peoples; Timothy J Vreeland Journal: Onco Targets Ther Date: 2021-06-01 Impact factor: 4.147
Authors: John Kokkinos; Anya Jensen; George Sharbeen; Joshua A McCarroll; David Goldstein; Koroush S Haghighi; Phoebe A Phillips Journal: Cancers (Basel) Date: 2021-05-17 Impact factor: 6.639